Related Experiment Videos
Do calcium antagonists protect the human hypertensive kidney?
1Department of Medicine, University of Missouri-Columbia School of Medicine 65212.
Insights
Calcium antagonists like amlodipine may preserve renal function in patients with hypertension. Further long-term studies are needed to confirm these benefits for kidney protection.
Area of Science:
- Nephrology
- Cardiology
- Pharmacology
Background:
- Essential hypertension and hypertension in advanced renal disease cause progressive kidney function decline.
- Controlling systemic and glomerular hypertension may slow renal deterioration.
Purpose of the Study:
- To evaluate the short-term effects of calcium antagonists on renal function in hypertensive patients.
- To determine the potential of calcium antagonists in attenuating kidney function decline.
Main Methods:
- Short-term laboratory studies involving calcium antagonists (amlodipine, diltiazem, nifedipine).
- Assessment of glomerular filtration, effective renal plasma flow, and urinary protein excretion.
Main Results:
- Calcium antagonists demonstrated preservation and/or improvement of renal function.
- No adverse effects were observed on glomerular filtration, effective renal plasma flow, or urinary protein excretion.
Conclusions:
- Short-term data suggest calcium antagonists may benefit renal function in hypertensive individuals.
- Long-term clinical trials are necessary to confirm sustained renal protection and efficacy against hypertension-induced kidney damage.
Abstract:
The natural course of essential hypertension, and hypertension associated with advanced renal parenchymal disease, is characterized by a progressive deterioration of renal function. If calcium antagonists can control both systemic and glomerular hypertension, they may be able to attenuate this process. Short-term studies in our laboratory suggest that the calcium antagonists amlodipine, diltiazem, and nifedipine preserve and/or improve renal function; there were no adverse effects on glomerular filtration, effective renal plasma flow, and/or urinary protein excretion. However, long-term clinical trials are required to determine if the observed short-term renal responses are sustained and if calcium antagonists protect the human kidney from systemic and glomerular hypertension.